Eric E. Poma - 22 Apr 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
22 Apr 2025
Transactions value $
$0
Form type
4
Filing time
25 Apr 2025, 06:05:05 UTC
Previous filing
25 Jan 2024
Next filing
25 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Stock Option (right to buy) Award +726K 726K 22 Apr 2025 Common Stock 726K $0.47 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 22, 2025 (the "Grant Date"), the compensation committee and board of directors of Calidi Biotherapeutics, Inc. ("Issuer") approved an inducement grant to the Reporting Person of 726,412 stock options (the "Options"), pursuant to the exception under Section 711 NYSE American, at a per share exercise price of $0.4690, which is equal to the closing price of the Issuer's common stock on the Grant Date.
F2 25% of the options will vest upon the one (1) year anniversary of 04/22/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer.

Remarks:

Exhibit 24 - Power of Attorney